IMPROVE DOSIMETRIC OUTCOME IN STAGE III NON-SMALL-CELL LUNG CANCER TREATMENT USING SPOT-SCANNING PROTON ARC (SPARC) THERAPY

Improve dosimetric outcome in stage III non-small-cell lung cancer treatment using spot-scanning proton arc (SPArc) therapy

Abstract Background To evaluate spot-scanning proton arc therapy (SPArc) and multi-field robust optimized intensity modulated proton therapy (RO-IMPT) in treating stage III non-small-cell lung cancer (NSCLC) patients.Methods Two groups of stage IIIA or IIIB NSCLC patients (group 1: eight patients with tumor motion less than 5 mm; group 2: six patie

read more

Subcutaneous advanced glycation end products, cardiovascular risk factors and vascular health during childhood development in a Swiss population

BackgroundSkin-derived advanced glycation end products (sAGEs) have been associated with cardiovascular (CV) risk and mortality in adults.We hypothesize that cardiorespiratory fitness (CRF), body mass index (BMI) and vascular health are associated with development of sAGEs during childhood.MethodsIn our prospective cohort study, 1171 children aged

read more